Filgotinib 200 mg demonstrated efficacy in treating perianal fistulising Crohn’s disease, with a higher proportion of participants achieving a combined fistula response compared to lower doses and placebo. Serious adverse events were more frequent with the 200 mg dose, but no treatment-related serious adverse events or deaths were reported. Filgotinib 200 mg was generally well tolerated, showing promise as a potential treatment option for this condition.
Multicenter Study by Reinisch W, Colombel JF (…) Gecse KB et 7 al. in J Crohns Colitis
© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.